FAQs about delivery changes

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

40.42 +2.57 (+6.79%)
Streaming Delayed Price Updated: 3:31 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX 
Via Benzinga
News headline image
Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients ↗
Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... 
Via Benzinga
News headline image
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
From NANOBIOTIX
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
News headline image
Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer ↗
Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink... 
Via Benzinga
News headline image
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
From NANOBIOTIX
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (... 
Via Benzinga
News headline image
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
From Nanobiotix
Via Business Wire
News headline image
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings ↗
Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in... 
Via Benzinga
News headline image
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX Announces First Quarter Operational and Financial Updates
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
From NANOBIOTIX
Via Business Wire
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers BioCryst Pharmaceuticals (NASDAQ:BCRX) shares rose 11.13% to $11.32 during Friday's regular session. As of 08:06 EST, this security is trading at a volume of 8... 
Via Benzinga
News headline image
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
From NANOBIOTIX
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article